Ascletis Submits IND Application to the U.S. FDA for ASC30_39 FDC, a Potentially First-in-Class Oral Small Molecule Fixed-Dose Combination of GLP-1R Agonist and Selective Amylin Receptor Agonist, for the Treatment of Obesity
- ASC30_39 FDC, a once-daily oral fixed-dose combination (FDC) tablet of small molecule GLP-1R agonist ASC30 and small molecule selective amylin receptor agonist ASC39, is the first co-formulation of an oral GLP-1 and an oral amylin to reach Investigational New Drug submission.
- ASC30_39 FDC demonstrated highly favorable pharmacokinetics with excellent oral bioavailability, high drug exposure and a long half-life.
- ASC30 is a once-daily oral small molecule GLP-1R agonist currently in two global pivotal Phase III studies (
- ASC39 demonstrated eloralintide-like amylin selectivity (40-fold for hAMY1R over hCTR) and efficacy in preclinical models.
- ASC30_39 FDC demonstrated excellent compatibility between ASC30 and ASC39, with room temperature stability and a small pill size.
"ASC30_39 FDC is the first co-formulation of an oral GLP-1 and an oral amylin to reach IND submission, combining two validated, complementary mechanisms for weight management in a single once-daily tablet." said
The IND submission builds upon the recent milestones of
About ASC30_39 FDC
Both ASC30 and ASC39 were discovered in-house utilizing
Dosed orally in dogs, ASC30_39 FDC tablets demonstrated excellent oral bioavailability, high drug exposure and a long half-life of up to 12 hours. These key pharmacokinetic parameters of ASC30_39 FDC are consistent with those observed for the respective monotherapies in a head-to-head dog study. (Press Release)
ASC30 is a once-daily oral small molecule GLP-1R agonist currently in two global pivotal Phase III studies (
ASC39 is a potent oral small molecule selective amylin receptor agonist that was 40-fold more selective for human amylin 1 receptor (hAMY1R) over human calcitonin receptor (hCTR) and produced a 6.6% placebo-adjusted body weight reduction after once-daily oral administration for six consecutive days in diet-induced obese (DIO) rats, similar to eloralintide at 5.6%. (Press Release)
About Ascletis Pharma Inc.
Ascletis Pharma Inc. (1672.HK) is a fully integrated biotechnology company focused on discovering, developing and commercializing potentially first-in-class and best-in-class therapeutics for metabolic diseases, including obesity and diabetes. Leveraging its proprietary Artificial Intelligence-Assisted Structure-Based Drug Discovery (AISBDD), Ultra-Long-Acting Platform (ULAP) and Peptide Oral Transport ENhancement Technology (POTENT), Ascletis has built a wholly in-house pipeline of oral small molecules and peptides targeting GLP-1R, GIPR, GCGR and amylin pathways. Ascletis is advancing a robust pipeline of 15 differentiated assets leveraged from six new molecular entities (three small molecules and three peptides), which are being developed both as monotherapies and in combination. Its lead program, ASC30, a once-daily oral small molecule GLP-1R agonist, is being evaluated in two global Phase III studies in obesity. The Company's pipeline also includes oral small molecule dual and triple agonist fixed-dose combinations, a selective amylin receptor agonist, injectable peptide agonists and combinations spanning dual to quadruple agonism designed for once-monthly to once-quarterly subcutaneous dosing, and oral peptide agonists and combinations designed for once-weekly dosing.
For more information, please visit www.ascletis.com.
Contact:
Peter Vozzo
ICR Healthcare
443-231-0505 (U.S.)
Peter.vozzo@icrhealthcare.com
Ascletis Pharma Inc. PR and IR Teams
+86-181-0650-9129 (China)
pr@ascletis.com / ir@ascletis.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ascletis-submits-ind-application-to-the-us-fda-for-asc3039-fdc-a-potentially-first-in-class-oral-small-molecule-fixed-dose-combination-of-glp-1r-agonist-and-selective-amylin-receptor-agonist-for-the-treatment-of-obesity-302935882.html
SOURCE Ascletis Pharma Inc.